Stifel Nicolaus Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $18.00

Elanco Animal Health (NYSE:ELAN) had its target price reduced by Stifel Nicolaus from $20.00 to $18.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages also recently weighed in on ELAN. Barclays upped their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group started coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They issued a “buy” rating and a $18.00 target price on the stock. Leerink Partners started coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.43.

Elanco Animal Health Stock Down 2.3 %

ELAN stock opened at $11.53 on Tuesday. Elanco Animal Health has a one year low of $11.28 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm’s fifty day moving average is $12.69 and its 200 day moving average is $13.54. The firm has a market cap of $5.70 billion, a PE ratio of 28.83, a P/E/G ratio of 1.96 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period last year, the firm earned $0.18 EPS. On average, research analysts forecast that Elanco Animal Health will post 0.92 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Commerce Bank grew its position in Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after acquiring an additional 741 shares during the period. HBK Sorce Advisory LLC increased its position in shares of Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock worth $186,000 after acquiring an additional 1,107 shares during the period. Keene & Associates Inc. raised its stake in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after acquiring an additional 1,240 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares during the period. Finally, M&T Bank Corp grew its stake in Elanco Animal Health by 5.9% during the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after purchasing an additional 1,464 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.